Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Leukemia - 36(2022), 12 vom: 14. Dez., Seite 2853-2862 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Driessen, Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 02.12.2022 Date Revised 04.09.2023 published: Print-Electronic ClinicalTrials.gov: NCT02280993 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-022-01717-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347567185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347567185 | ||
| 003 | DE-627 | ||
| 005 | 20231226034132.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01717-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347567185 | ||
| 035 | |a (NLM)36241696 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Driessen, Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.12.2022 | ||
| 500 | |a Date Revised 04.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02280993 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Brentuximab Vedotin |2 NLM | |
| 650 | 7 | |a 7XL5ISS668 |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 700 | 1 | |a Kersten, Marie José |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a van den Berg, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Tonino, Sanne H |e verfasserin |4 aut | |
| 700 | 1 | |a Zijlstra, Josée M |e verfasserin |4 aut | |
| 700 | 1 | |a Lugtenburg, Pieternella J |e verfasserin |4 aut | |
| 700 | 1 | |a Morschhauser, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Hutchings, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Amorim, Sandy |e verfasserin |4 aut | |
| 700 | 1 | |a Gastinne, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Nijland, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Zwezerijnen, Gerben J C |e verfasserin |4 aut | |
| 700 | 1 | |a Boellaard, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a de Vet, Henrica C W |e verfasserin |4 aut | |
| 700 | 1 | |a Arens, Anne I J |e verfasserin |4 aut | |
| 700 | 1 | |a Valkema, Roelf |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Roberto D K |e verfasserin |4 aut | |
| 700 | 1 | |a Drees, Esther E E |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Daphne |e verfasserin |4 aut | |
| 700 | 1 | |a Plattel, Wouter J |e verfasserin |4 aut | |
| 700 | 1 | |a Diepstra, Arjan |e verfasserin |4 aut | |
| 700 | 0 | |a HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 36(2022), 12 vom: 14. Dez., Seite 2853-2862 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:12 |g day:14 |g month:12 |g pages:2853-2862 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-022-01717-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 12 |b 14 |c 12 |h 2853-2862 | ||